{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:11:02Z","timestamp":1793034662954,"version":"4.5.0"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82071769"],"award-info":[{"award-number":["No. 82071769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-025-00749-z","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:22:23Z","timestamp":1750069343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management"],"prefix":"10.1186","volume":"30","author":[{"given":"YuXian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzheqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-9650","authenticated-orcid":false,"given":"Yaoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"17","key":"749_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR. Systemic Lupus erythematosus: a review. JAMA. 2024;331(17):1480\u201391.","journal-title":"JAMA"},{"key":"749_CR2","doi-asserted-by":"crossref","unstructured":"Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172 (11):Itc81-itc96.","DOI":"10.7326\/AITC202006020"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","volume":"41","author":"S Caielli","year":"2023","unstructured":"Caielli S, Wan Z, Pascual V. Systemic Lupus erythematosus pathogenesis: interferon and beyond. Annu Rev Immunol. 2023;41:533\u201360.","journal-title":"Annu Rev Immunol"},{"key":"749_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109946","volume":"118","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhao M, Gong N, Zhang F, Chen W, Liu Y. Immunometabolomics provides a new perspective for studying systemic lupus erythematosus. Int Immunopharmacol. 2023;118: 109946.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"749_CR5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos GC. The immunology of systemic lupus erythematosus. Nat Immunol. 2024;25(8):1332\u201343.","journal-title":"Nat Immunol"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","volume":"74","author":"S Lazar","year":"2023","unstructured":"Lazar S, Kahlenberg JM. Systemic Lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med. 2023;74:339\u201352.","journal-title":"Annu Rev Med"},{"issue":"5","key":"749_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12026-022-09296-7","volume":"70","author":"R Fakhfakh","year":"2022","unstructured":"Fakhfakh R, Zian Z, Elloumi N, Abida O, Bouallegui E, Houssaini H, et\u00a0al. Th17 and Th1 cells in systemic lupus erythematosus with focus on lupus nephritis. Immunol Res. 2022;70(5):644\u201353.","journal-title":"Immunol Res"},{"issue":"4","key":"749_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4049\/jimmunol.1901175","volume":"204","author":"SB Chodisetti","year":"2020","unstructured":"Chodisetti SB, Fike AJ, Domeier PP, Singh H, Choi NM, Corradetti C, et\u00a0al. Type II but not type I IFN signaling is indispensable for TLR7-promoted development of autoreactive B cells and systemic autoimmunity. J Immunol. 2020;204(4):796\u2013809.","journal-title":"J Immunol"},{"issue":"11","key":"749_CR9","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","volume":"75","author":"ME Munroe","year":"2016","unstructured":"Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et\u00a0al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014\u201321.","journal-title":"Ann Rheum Dis"},{"key":"749_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102869","volume":"132","author":"KZ Siddiqi","year":"2022","unstructured":"Siddiqi KZ, Zinglersen AH, Iversen KK, Rasmussen NS, Nielsen CT, Jacobsen S. A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus. J Autoimmun. 2022;132: 102869.","journal-title":"J Autoimmun"},{"issue":"10","key":"749_CR11","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s10067-018-4138-7","volume":"37","author":"M Liu","year":"2018","unstructured":"Liu M, Liu J, Hao S, Wu P, Zhang X, Xiao Y, et\u00a0al. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity. Clin Rheumatol. 2018;37(10):2675\u201384.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"749_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250319","volume":"53","author":"GM Moneta","year":"2023","unstructured":"Moneta GM, Bracaglia C, Caiello I, Farroni C, Pires Marafon D, Carlomagno R, et\u00a0al. Persistently active interferon-\u03b3 pathway and expansion of T-bet (+) B cells in a subset of patients with childhood-onset systemic lupus erythematosus. Eur J Immunol. 2023;53(7): e2250319.","journal-title":"Eur J Immunol"},{"issue":"12","key":"749_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1172\/jci.insight.138345","volume":"5","author":"A Fava","year":"2020","unstructured":"Fava A, Buyon J, Mohan C, Zhang T, Belmont HM, Izmirly P, et\u00a0al. Integrated urine proteomics and renal single-cell genomics identify an IFN-\u03b3 response gradient in lupus nephritis. JCI Insight. 2020;5(12):2.","journal-title":"JCI Insight"},{"issue":"4","key":"749_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/keab530","volume":"61","author":"RB Frittoli","year":"2022","unstructured":"Frittoli RB, Pereira DR, Lapa AT, Postal M, Sinicato NA, Fernandes PT, et\u00a0al. Axonal dysfunction is associated with interferon-\u03b3 levels in childhood-onset systemic lupus erythematosus: a multivoxel magnetic resonance spectroscopy study. Rheumatology. 2022;61(4):1529\u201337.","journal-title":"Rheumatology"},{"issue":"5","key":"749_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.immuni.2012.10.010","volume":"37","author":"SK Lee","year":"2012","unstructured":"Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP, et\u00a0al. Interferon-\u03b3 excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity. 2012;37(5):880\u201392.","journal-title":"Immunity"},{"issue":"25","key":"749_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.aat1604","volume":"3","author":"CM Lloyd","year":"2018","unstructured":"Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol. 2018;3(25):1.","journal-title":"Sci Immunol"},{"issue":"5","key":"749_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/art.42778","volume":"76","author":"GA Ramirez","year":"2024","unstructured":"Ramirez GA, Tassi E, Noviello M, Mazzi BA, Moroni L, Citterio L, et\u00a0al. Histone-Specific CD4 (+) T cell plasticity in active and quiescent systemic Lupus erythematosus. Arthritis Rheumatol. 2024;76(5):739\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"749_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2024.02.018","volume":"57","author":"L Shehata","year":"2024","unstructured":"Shehata L, Thouvenel CD, Hondowicz BD, Pew LA, Pritchard GH, Rawlings DJ, et\u00a0al. Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers. Immunity. 2024;57(4):843-58.e5.","journal-title":"Immunity"},{"issue":"11","key":"749_CR19","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","volume":"105","author":"GP Sims","year":"2005","unstructured":"Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390\u20138.","journal-title":"Blood"},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3389\/fimmu.2019.02050","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Hu Q, Zhang M, Yang F, Peng C, Zhang Z, et\u00a0al. Bach2 deficiency leads to spontaneous expansion of IL-4-producing T follicular helper cells and autoimmunity. Front Immunol. 2019;10:2050.","journal-title":"Front Immunol"},{"issue":"11","key":"749_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1136\/ard-2023-224453","volume":"82","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang Z, Kang Z, Zhou XJ, Liu S, Guo S, et\u00a0al. Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus. Ann Rheum Dis. 2023;82(11):1444\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"749_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13002","volume":"93","author":"A Res\u00e9ndiz-Mora","year":"2021","unstructured":"Res\u00e9ndiz-Mora A, Wong-Baeza C, Nev\u00e1rez-Lechuga I, Landa-Sald\u00edvar C, Molina-G\u00f3mez E, Hern\u00e1ndez-Pando R, et\u00a0al. Interleukin 4 deficiency limits the development of a lupus-like disease in mice triggered by phospholipids in a non-bilayer arrangement. Scand J Immunol. 2021;93(3): e13002.","journal-title":"Scand J Immunol"},{"issue":"6","key":"749_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom13060974","volume":"13","author":"A Winikajtis-Burzy\u0144ska","year":"2023","unstructured":"Winikajtis-Burzy\u0144ska A, Brzosko M, Przepiera-B\u0119dzak H. Increased serum interleukin 10 levels are associated with increased disease activity and increased risk of anti-ss-a\/ro antibody positivity in patients with systemic lupus erythematosus. Biomolecules. 2023;13(6):1.","journal-title":"Biomolecules"},{"issue":"1","key":"749_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/S1807-59322011000100014","volume":"66","author":"JR Carneiro","year":"2011","unstructured":"Carneiro JR, Fuzii HT, Kayser C, Alberto FL, Soares FA, Sato EI, et\u00a0al. IL-2, IL-5, TNF-\u03b1 and IFN-\u03b3 mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics. 2011;66(1):77\u201382.","journal-title":"Clinics"},{"issue":"6","key":"749_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916934.2015.1037441","volume":"48","author":"D Li","year":"2015","unstructured":"Li D, Guo B, Wu H, Tan L, Chang C, Lu Q. Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity. 2015;48(6):353\u201361.","journal-title":"Autoimmunity"},{"key":"749_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109803","volume":"116","author":"J Wu","year":"2023","unstructured":"Wu J, Li Y, Feng D, Yu Y, Long H, Hu Z, et\u00a0al. Integrated analysis of ATAC-seq and RNA-seq reveals the transcriptional regulation network in SLE. Int Immunopharmacol. 2023;116: 109803.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"749_CR27","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41423-020-00540-4","volume":"18","author":"K Ma","year":"2021","unstructured":"Ma K, Du W, Xiao F, Han M, Huang E, Peng N, et\u00a0al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell Mol Immunol. 2021;18(7):1739\u201350.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"749_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/BOR.0000000000000132","volume":"27","author":"JP Sherlock","year":"2015","unstructured":"Sherlock JP, Taylor PC, Buckley CD. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Curr Opin Rheumatol. 2015;27(1):71\u20135.","journal-title":"Curr Opin Rheumatol"},{"key":"749_CR29","first-page":"1","volume":"17","author":"MM Haroon","year":"2023","unstructured":"Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH. Significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices. Biologics. 2023;17:1\u20139.","journal-title":"Biologics"},{"issue":"10","key":"749_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrrheum.2015.128","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(10):562.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"749_CR31","doi-asserted-by":"publisher","first-page":"F679","DOI":"10.1152\/ajprenal.00236.2017","volume":"314","author":"R Sharma","year":"2018","unstructured":"Sharma R, Kinsey GR. Regulatory T cells in acute and chronic kidney diseases. Am J Physiol Renal Physiol. 2018;314(5):F679\u201398.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"749_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/09612033221083269","volume":"31","author":"M Kamal","year":"2022","unstructured":"Kamal M, Gabr H, Anwar S, Bastawy S, Salah L. The relation of CD4 (+)CD25+Foxp3+ regulatory T cells concentration with disease activity and damage index in systemic lupus erythematosus. Lupus. 2022;31(4):463\u201371.","journal-title":"Lupus"},{"issue":"6","key":"749_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111606","volume":"41","author":"C Guo","year":"2022","unstructured":"Guo C, Liu Q, Zong D, Zhang W, Zuo Z, Yu Q, et\u00a0al. Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus. Cell Rep. 2022;41(6): 111606.","journal-title":"Cell Rep"},{"issue":"10","key":"749_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648\u201359.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"749_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/art.40014","volume":"69","author":"D Comte","year":"2017","unstructured":"Comte D, Karampetsou MP, Kis-Toth K, Yoshida N, Bradley SJ, Kyttaris VC, et\u00a0al. Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2. Arthritis Rheumatol. 2017;69(4):808\u201313.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"749_CR36","doi-asserted-by":"publisher","first-page":"8304","DOI":"10.1038\/s41467-024-52617-7","volume":"15","author":"E Katsuyama","year":"2024","unstructured":"Katsuyama E, Humbel M, Suarez-Fueyo A, Satyam A, Yoshida N, Kyttaris VC, et\u00a0al. CD38 in SLE CD4 T cells promotes Ca (2+) flux and suppresses interleukin-2 production by enhancing the expression of GM2 on the surface membrane. Nat Commun. 2024;15(1):8304.","journal-title":"Nat Commun"},{"issue":"33","key":"749_CR37","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1073\/pnas.1605081113","volume":"113","author":"D Comte","year":"2016","unstructured":"Comte D, Karampetsou MP, Kis-Toth K, Yoshida N, Bradley SJ, Mizui M, et\u00a0al. Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2016;113(33):9321\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"749_CR38","doi-asserted-by":"publisher","first-page":"12209","DOI":"10.3390\/ijms232012209","volume":"23","author":"K Szab\u00f3","year":"2022","unstructured":"Szab\u00f3 K, J\u00e1mbor I, P\u00e1zm\u00e1ndi K, Nagy N, Papp G, Tarr T. Altered circulating follicular T helper cell subsets and follicular T regulatory cells are indicators of a derailed B cell response in lupus, which could be modified by targeting IL-21R. Int J Mol Sci. 2022;23(20):12209.","journal-title":"Int J Mol Sci"},{"issue":"8022","key":"749_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law C, Wacleche VS, Cao Y, Pillai A, Sowerby J, Hancock B, et\u00a0al. Interferon subverts an AHR-JUN axis to promote CXCL13 (+) T cells in lupus. Nature. 2024;631(8022):857\u201366.","journal-title":"Nature"},{"key":"749_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949334","volume":"9","author":"M Mao","year":"2022","unstructured":"Mao M, Xu S, Lin L, Dong D, Xue M, He S, et\u00a0al. Impact of corticosteroids on the proportions of circulating Tfh cell subsets in patients with systemic lupus erythematous. Front Med. 2022;9: 949334.","journal-title":"Front Med"},{"key":"749_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928359","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin X, Chen J, Wu J, Lu Y, Li B, Fu W, et\u00a0al. Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus. Front Immunol. 2022;13: 928359.","journal-title":"Front Immunol"},{"issue":"1","key":"749_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-024-03394-7","volume":"26","author":"T Khunsri","year":"2024","unstructured":"Khunsri T, Thawornpan P, Tianpothong P, Suangtamai T, Ngamjanyaporn P, Leepiyasakulchai C, et\u00a0al. Activation of circulating TFH17 cells associated with activated naive and double negative 2 B cell expansion, and disease activity in systemic lupus erythematosus patients. Arthritis Res Ther. 2024;26(1):159.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"749_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/ard-2023-225433","volume":"83","author":"AG Ferret\u00e9-Bonastre","year":"2024","unstructured":"Ferret\u00e9-Bonastre AG, Mart\u00ednez-Gallo M, Morante-Palacios O, Calvillo CL, Calafell-Segura J, Rodr\u00edguez-Ubreva J, et\u00a0al. Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus. Ann Rheum Dis. 2024;83(7):865\u201378.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"749_CR44","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39209","volume":"67","author":"M Akiyama","year":"2015","unstructured":"Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, et\u00a0al. Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease. Arthritis Rheumatol. 2015;67(9):2476\u201381.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"749_CR45","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1038\/s41467-024-47691-w","volume":"15","author":"J Tchen","year":"2024","unstructured":"Tchen J, Simon Q, Chapart L, Thaminy MK, Vibhushan S, Saveanu L, et\u00a0al. PD-L1- and IL-4-expressing basophils promote pathogenic accumulation of T follicular helper cells in lupus. Nat Commun. 2024;15(1):3389.","journal-title":"Nat Commun"},{"issue":"5","key":"749_CR46","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/art.40038","volume":"69","author":"D Comte","year":"2017","unstructured":"Comte D, Karampetsou MP, Yoshida N, Kis-Toth K, Kyttaris VC, Tsokos GC. Signaling lymphocytic activation molecule family member 7 engagement restores defective effector CD8+ T cell function in systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1035\u201344.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"749_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","volume":"30","author":"E Katsuyama","year":"2020","unstructured":"Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, et\u00a0al. The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 2020;30(1):112-23.e4.","journal-title":"Cell Rep"},{"issue":"6589","key":"749_CR48","doi-asserted-by":"publisher","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","volume":"376","author":"RK Perez","year":"2022","unstructured":"Perez RK, Gordon MG, Subramaniam M, Kim MC, Hartoularos GC, Targ S, et\u00a0al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science. 2022;376(6589):eabf1970.","journal-title":"Science"},{"key":"749_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","volume":"141","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92\u2013103.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"749_CR50","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","volume":"76","author":"C Chamberlain","year":"2017","unstructured":"Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, et\u00a0al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017;76(11):1837\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"749_CR51","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, D\u00f6rner T, Leon MG, Leszczy\u0144ski P, Urowitz M, et\u00a0al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology. 2021;60(11):5397\u2013407.","journal-title":"Rheumatology"},{"issue":"7","key":"749_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/art.40479","volume":"70","author":"LE Cheng","year":"2018","unstructured":"Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, et\u00a0al. Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis. Arthritis Rheumatol. 2018;70(7):1071\u20136.","journal-title":"Arthritis Rheumatol"},{"key":"749_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. Int Immunopharmacol. 2020;80: 106221.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"749_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12721","volume":"287","author":"N Mitsuiki","year":"2019","unstructured":"Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev. 2019;287(1):33\u201349.","journal-title":"Immunol Rev"},{"issue":"10","key":"749_CR55","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D\u2019Cruz D, Wallace DJ, et\u00a0al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077\u201387.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"749_CR56","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/art.39248","volume":"67","author":"AA Welcher","year":"2015","unstructured":"Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, et\u00a0al. Blockade of interferon-\u03b3 normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(10):2713\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"749_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103262","volume":"22","author":"V Erazo-Mart\u00ednez","year":"2023","unstructured":"Erazo-Mart\u00ednez V, Tob\u00f3n GJ, Ca\u00f1as CA. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus. Autoimmun Rev. 2023;22(2): 103262.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"749_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1368","volume":"12","author":"S Wang","year":"2024","unstructured":"Wang S, Cui Y. Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis. Immun Inflamm Dis. 2024;12(8): e1368.","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"749_CR59","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.41179","volume":"72","author":"RF van Vollenhoven","year":"2020","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et\u00a0al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"749_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/art.41547","volume":"73","author":"M Cesaroni","year":"2021","unstructured":"Cesaroni M, Seridi L, Loza MJ, Schreiter J, Sweet K, Franks C, et\u00a0al. Suppression of serum interferon-\u03b3 levels as a potential measure of response to ustekinumab treatment in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(3):472\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"749_CR61","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven RF, Kalunian KC, D\u00f6rner T, Hahn BH, Tanaka Y, Gordon RM, et\u00a0al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81(11):1556\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"749_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et\u00a0al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"749_CR63","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, et\u00a0al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022;81(12):1685\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"749_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-023-01350-6","volume":"8","author":"H Zhou","year":"2023","unstructured":"Zhou H, Zhao X, Zhang R, Miao M, Pei W, Li Z, et\u00a0al. Low-dose IL-2 mitigates glucocorticoid-induced treg impairment and promotes improvement of SLE. Signal Transduct Target Ther. 2023;8(1):141.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"749_CR65","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","volume":"57","author":"ME Raeber","year":"2024","unstructured":"Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, et\u00a0al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024;57(9):2232-50.e10.","journal-title":"Immunity"},{"key":"749_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100152","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, et\u00a0al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J Transl Autoimmun. 2022;5: 100152.","journal-title":"J Transl Autoimmun"},{"issue":"10","key":"749_CR67","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/art.38091","volume":"65","author":"JC Szepietowski","year":"2013","unstructured":"Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, et\u00a0al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2661\u201371.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"749_CR68","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et\u00a0al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542\u201352.","journal-title":"Arthritis Rheum"},{"key":"749_CR69","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","volume":"11","author":"Q Hu","year":"2023","unstructured":"Hu Q, Bian Q, Rong D, Wang L, Song J, Huang HS, et\u00a0al. JAK\/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11:1110765.","journal-title":"Front Bioeng Biotechnol"},{"key":"749_CR70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mce.2017.01.035","volume":"451","author":"I Cornez","year":"2017","unstructured":"Cornez I, Yajnanarayana SP, Wolf AM, Wolf D. JAK\/STAT disruption induces immuno-deficiency: rationale for the development of JAK inhibitors as immunosuppressive drugs. Mol Cell Endocrinol. 2017;451:88\u201396.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"749_CR71","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et\u00a0al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391.","journal-title":"Nat Commun"},{"issue":"1","key":"749_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","volume":"24","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner T, van Vollenhoven RF, Doria A, Jia B, Ross Terres JA, Silk ME, et\u00a0al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24(1):112.","journal-title":"Arthritis Res Ther"},{"key":"749_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000424","author":"T D\u00f6rner","year":"2020","unstructured":"D\u00f6rner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, et\u00a0al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med. 2020. https:\/\/doi.org\/10.1136\/lupus-2020-000424.","journal-title":"Lupus Sci Med"},{"issue":"10381","key":"749_CR74","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, Tanaka Y, Morand EF, Kalunian KC, et\u00a0al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011\u20139.","journal-title":"Lancet"},{"issue":"10381","key":"749_CR75","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et\u00a0al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001\u201310.","journal-title":"Lancet"},{"issue":"10","key":"749_CR76","first-page":"1518","volume":"76","author":"JT Merrill","year":"2024","unstructured":"Merrill JT, Tanaka Y, D\u2019Cruz D, Vila-Rivera K, Siri D, Zeng X, et\u00a0al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial. Arthritis Rheumatol. 2024;76(10):1518\u201329.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"749_CR77","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.42750","volume":"76","author":"C Dong","year":"2024","unstructured":"Dong C, Guo Y, Chen Z, Li T, Ji J, Sun C, et\u00a0al. Single-cell profiling of bone marrow B cells and early B cell developmental disorders associated with systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(4):599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"749_CR78","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ni.3175","volume":"16","author":"CM Tipton","year":"2015","unstructured":"Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et\u00a0al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol. 2015;16(7):755\u201365.","journal-title":"Nat Immunol"},{"key":"749_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000739","author":"K Wangriatisak","year":"2022","unstructured":"Wangriatisak K, Kochayoo P, Thawornpan P, Leepiyasakulchai C, Suangtamai T, Ngamjanyaporn P, et\u00a0al. CD4 (+) T-cell cooperation promoted pathogenic function of activated na\u00efve B cells of patients with SLE. Lupus Sci Med. 2022. https:\/\/doi.org\/10.1136\/lupus-2022-000739.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"749_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13427","volume":"101","author":"K Wangriatisak","year":"2025","unstructured":"Wangriatisak K, de Vries C, Sharma RK, Huang W, Gr\u00f6nwall C, Pisitkun P, et\u00a0al. Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients. Scand J Immunol. 2025;101(1): e13427.","journal-title":"Scand J Immunol"},{"key":"749_CR81","doi-asserted-by":"publisher","first-page":"1093208","DOI":"10.3389\/fimmu.2023.1093208","volume":"14","author":"L Wen","year":"2023","unstructured":"Wen L, Zhang B, Wu X, Liu R, Fan H, Han L, et\u00a0al. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus. Front Immunol. 2023;14:1093208.","journal-title":"Front Immunol"},{"issue":"5","key":"749_CR82","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.immuni.2011.10.011","volume":"35","author":"SK O'Neill","year":"2011","unstructured":"O\u2019Neill SK, Getahun A, Gauld SB, Merrell KT, Tamir I, Smith MJ, et\u00a0al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity. 2011;35(5):746\u201356.","journal-title":"Immunity"},{"issue":"12","key":"749_CR83","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.4049\/jimmunol.1301169","volume":"191","author":"S Pathak","year":"2013","unstructured":"Pathak S, Ma S, Shukla V, Lu R. A role for IRF8 in B cell anergy. J Immunol. 2013;191(12):6222\u201330.","journal-title":"J Immunol"},{"issue":"9","key":"749_CR84","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.4049\/jimmunol.1302897","volume":"192","author":"Y Liu","year":"2014","unstructured":"Liu Y, Liu A, Iikuni N, Xu H, Shi FD, La Cava A. Regulatory CD4+ T cells promote B cell anergy in murine lupus. J Immunol. 2014;192(9):4069\u201373.","journal-title":"J Immunol"},{"issue":"12","key":"749_CR85","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","volume":"20","author":"T D\u00f6rner","year":"2024","unstructured":"D\u00f6rner T, Lipsky PE. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2024;20(12):770\u201382.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"749_CR86","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/art.42157","volume":"74","author":"F Szelinski","year":"2022","unstructured":"Szelinski F, Stefanski AL, Schrezenmeier E, Rincon-Arevalo H, Wiedemann A, Reiter K, et\u00a0al. Plasmablast-like phenotype among antigen-experienced CXCR5-CD19 (low) B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2022;74(9):1556\u201368.","journal-title":"Arthritis Rheumatol"},{"key":"749_CR87","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2012.00302","volume":"3","author":"DA Kaminski","year":"2012","unstructured":"Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic profiling. Front Immunol. 2012;3:302.","journal-title":"Front Immunol"},{"issue":"1","key":"749_CR88","first-page":"32","volume":"54","author":"J Kosalka","year":"2016","unstructured":"Kosalka J, Jakiela B, Musial J. Changes of memory B- and T-cell subsets in lupus nephritis patients. Folia Histochem Cytobiol. 2016;54(1):32\u201341.","journal-title":"Folia Histochem Cytobiol"},{"issue":"5","key":"749_CR89","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s10067-022-06051-z","volume":"41","author":"W Zhang","year":"2022","unstructured":"Zhang W, Wang YF, Hu FL, Lu FA, Wu T, Feng YL, et\u00a0al. Dysfunction of CD27 (+)IgD (+) B cells correlates with aggravated systemic lupus erythematosus. Clin Rheumatol. 2022;41(5):1551\u20139.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"749_CR90","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaut.2009.11.002","volume":"34","author":"AS Korganow","year":"2010","unstructured":"Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL, et\u00a0al. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun. 2010;34(4):426\u201334.","journal-title":"J Autoimmun"},{"issue":"3","key":"749_CR91","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/ar3042","volume":"12","author":"B Rodr\u00edguez-Bayona","year":"2010","unstructured":"Rodr\u00edguez-Bayona B, Ramos-Amaya A, P\u00e9rez-Venegas JJ, Rodr\u00edguez C, Brieva JA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther. 2010;12(3):R108.","journal-title":"Arthritis Res Ther"},{"key":"749_CR92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fmed.2020.00085","volume":"7","author":"X You","year":"2020","unstructured":"You X, Zhang R, Shao M, He J, Chen J, Liu J, et\u00a0al. Double negative B cell is associated with renal impairment in systemic lupus erythematosus and acts as a marker for nephritis remission. Front Med. 2020;7:85.","journal-title":"Front Med"},{"issue":"3","key":"749_CR93","doi-asserted-by":"publisher","first-page":"311","DOI":"10.31138\/mjr.31.3.311","volume":"31","author":"A Sachinidis","year":"2020","unstructured":"Sachinidis A, Xanthopoulos K, Garyfallos A. Age-associated B cells (ABCs) in the prognosis, diagnosis and therapy of systemic lupus erythematosus (SLE). Mediterr J Rheumatol. 2020;31(3):311\u20138.","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"749_CR94","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/art.42776","volume":"76","author":"K Manion","year":"2024","unstructured":"Manion K, Mu\u00f1oz-Grajales C, Kim M, Atenafu E, Faheem Z, Gladman DD, et\u00a0al. Different immunologic profiles are associated with distinct clinical phenotypes in longitudinally observed patients with systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(5):726\u201338.","journal-title":"Arthritis Rheumatol"},{"issue":"6681","key":"749_CR95","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.adf8531","volume":"383","author":"D Dai","year":"2024","unstructured":"Dai D, Gu S, Han X, Ding H, Jiang Y, Zhang X, et\u00a0al. The transcription factor ZEB2 drives the formation of age-associated B cells. Science. 2024;383(6681):413\u201321.","journal-title":"Science"},{"issue":"1","key":"749_CR96","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et\u00a0al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c (hi)T-bet (+) B cells in SLE. Nat Commun. 2018;9(1):1758.","journal-title":"Nat Commun"},{"key":"749_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","volume":"12","author":"D Catal\u00e1n","year":"2021","unstructured":"Catal\u00e1n D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguill\u00f3n JC, et\u00a0al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12: 611795.","journal-title":"Front Immunol"},{"issue":"1","key":"749_CR98","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s42358-022-00279-8","volume":"62","author":"H Xiong","year":"2022","unstructured":"Xiong H, Tang Z, Xu Y, Shi Z, Guo Z, Liu X, et\u00a0al. CD19 (+)CD24 (high)CD27 (+) B cell and interleukin 35 as potential biomarkers of disease activity in systemic lupus erythematosus patients. Adv Rheumatol. 2022;62(1):48.","journal-title":"Adv Rheumatol"},{"issue":"8","key":"749_CR99","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1177\/1352458520951536","volume":"27","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Ali R, Nicholas R, Muraro PA. Defective CD19+CD24 (hi)CD38 (hi) transitional B-cell function in patients with relapsing-remitting MS. Mult Scler. 2021;27(8):1187\u201397.","journal-title":"Mult Scler"},{"issue":"6","key":"749_CR100","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1756-185X.12229","volume":"16","author":"L Jin","year":"2013","unstructured":"Jin L, Weiqian C, Lihuan Y. Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in na\u00efve systemic lupus erythematosus. Int J Rheum Dis. 2013;16(6):698\u2013708.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"749_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/03009742.2015.1126346","volume":"45","author":"K Heinemann","year":"2016","unstructured":"Heinemann K, Wilde B, Hoerning A, Tebbe B, Kribben A, Witzke O, et\u00a0al. Decreased IL-10 (+) regulatory B cells (Bregs) in lupus nephritis patients. Scand J Rheumatol. 2016;45(4):312\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"749_CR102","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ekir.2020.04.019","volume":"5","author":"N Girimaji","year":"2020","unstructured":"Girimaji N, Kaundal U, Rathi M, Sharma A, Nada R, Ramachandran R, et\u00a0al. Regulatory B and T cells and their association with clinical response in new-onset lupus nephritis patients. Kidney Int Rep. 2020;5(7):1081\u20136.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"749_CR103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41392-022-00948-6","volume":"7","author":"XY Wang","year":"2022","unstructured":"Wang XY, Wei Y, Hu B, Liao Y, Wang X, Wan WH, et\u00a0al. c-Myc-driven glycolysis polarizes functional regulatory B cells that trigger pathogenic inflammatory responses. Signal Transduct Target Ther. 2022;7(1):105.","journal-title":"Signal Transduct Target Ther"},{"key":"749_CR104","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3389\/fimmu.2019.02768","volume":"10","author":"PD Pioli","year":"2019","unstructured":"Pioli PD. Plasma cells, the next generation: beyond antibody secretion. Front Immunol. 2019;10:2768.","journal-title":"Front Immunol"},{"issue":"2","key":"749_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152347","volume":"228","author":"Y Mei","year":"2023","unstructured":"Mei Y, Xin Y, Li X, Yin H, Xiong F, Yang M, et\u00a0al. Aberrant expression of JMJD3 in SLE promotes B-cell differentiation. Immunobiology. 2023;228(2): 152347.","journal-title":"Immunobiology"},{"issue":"4","key":"749_CR106","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, V\u00f6lkl S, Aigner M, Bozec A, et\u00a0al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of b cells in systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(4):497\u2013504.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"749_CR107","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.1038\/s41467-022-35209-1","volume":"13","author":"M Zheng","year":"2022","unstructured":"Zheng M, Hu Z, Mei X, Ouyang L, Song Y, Zhou W, et\u00a0al. Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. Nat Commun. 2022;13(1):7489.","journal-title":"Nat Commun"},{"key":"749_CR108","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","volume":"71","author":"R Cornelis","year":"2021","unstructured":"Cornelis R, Chang HD, Radbruch A. Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol. 2021;71:97\u2013102.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"749_CR109","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et\u00a0al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 2023;75(12):2185\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"749_CR110","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/ard.2007.079095","volume":"67","author":"T J\u00f3nsd\u00f3ttir","year":"2008","unstructured":"J\u00f3nsd\u00f3ttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"749_CR111","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/rheumatology\/keq055","volume":"49","author":"T J\u00f3nsd\u00f3ttir","year":"2010","unstructured":"J\u00f3nsd\u00f3ttir T, Gunnarsson I, Mour\u00e3o AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology. 2010;49(8):1502\u20134.","journal-title":"Rheumatology"},{"issue":"8","key":"749_CR112","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et\u00a0al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"749_CR113","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et\u00a0al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580\u201390.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"749_CR114","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et\u00a0al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"749_CR115","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et\u00a0al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"749_CR116","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-017-0707-z","volume":"19","author":"SC Liossis","year":"2017","unstructured":"Liossis SC, Staveri C. B cell-based treatments in SLE: past experience and current directions. Curr Rheumatol Rep. 2017;19(12):78.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"749_CR117","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","volume":"25","author":"F Catapano","year":"2010","unstructured":"Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25(11):3586\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"749_CR118","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12016-016-8551-x","volume":"52","author":"E Favoino","year":"2017","unstructured":"Favoino E, Prete M, Marzullo A, Millo E, Shoenfeld Y, Perosa F. CD20-mimotope peptide active immunotherapy in systemic lupus erythematosus and a reappraisal of vaccination strategies in rheumatic diseases. Clin Rev Allergy Immunol. 2017;52(2):217\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"749_CR119","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et\u00a0al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368\u201379.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"749_CR120","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","volume":"21","author":"V Reddy","year":"2016","unstructured":"Reddy V, Dahal LN, Cragg MS, Leandro M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016;21(8):1330\u20138.","journal-title":"Drug Discov Today"},{"issue":"7","key":"749_CR121","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","volume":"57","author":"S Masoud","year":"2018","unstructured":"Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology. 2018;57(7):1156\u201361.","journal-title":"Rheumatology"},{"issue":"12","key":"749_CR122","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","volume":"61","author":"J Arnold","year":"2022","unstructured":"Arnold J, Dass S, Twigg S, Jones CH, Rhodes B, Hewins P, et\u00a0al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology. 2022;61(12):4905\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"749_CR123","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et\u00a0al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"749_CR124","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Zuta Santill\u00e1n AE, et\u00a0al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"749_CR125","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13075-015-0686-2","volume":"17","author":"V Fleischer","year":"2015","unstructured":"Fleischer V, Sieber J, Fleischer SJ, Shock A, Heine G, Daridon C, et\u00a0al. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-\u03b1, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. Arthritis Res Ther. 2015;17(1):185.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"749_CR126","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/ar3179","volume":"12","author":"C Daridon","year":"2010","unstructured":"Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, et\u00a0al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(6):R204.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"749_CR127","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","volume":"52","author":"DJ Wallace","year":"2013","unstructured":"Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et\u00a0al. Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology. 2013;52(7):1313\u201322.","journal-title":"Rheumatology"},{"issue":"1","key":"749_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et\u00a0al. Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"749_CR129","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczy\u0144ski P, et\u00a0al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind. Placebo-Controlled Trials Arthritis Rheumatol. 2017;69(2):362\u201375.","journal-title":"Placebo-Controlled Trials Arthritis Rheumatol"},{"issue":"1","key":"749_CR130","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","volume":"20","author":"S Cole","year":"2018","unstructured":"Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, et\u00a0al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):85.","journal-title":"Arthritis Res Ther"},{"key":"749_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645478","volume":"12","author":"M Humbel","year":"2021","unstructured":"Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, et\u00a0al. Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE. Front Immunol. 2021;12: 645478.","journal-title":"Front Immunol"},{"issue":"1","key":"749_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2023-001112","volume":"11","author":"SRP McDonnell","year":"2024","unstructured":"McDonnell SRP, Nguyen VA, Walton NM, Merkwirth C, Hong F, Berg D, et\u00a0al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci Med. 2024;11(1):1.","journal-title":"Lupus Sci Med"},{"issue":"12","key":"749_CR133","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/jcph.1278","volume":"58","author":"C Schwabe","year":"2018","unstructured":"Schwabe C, Rosenstock B, Doan T, Hamilton P, Dunbar PR, Eleftheraki AG, et\u00a0al. Safety, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 655064, an antagonistic anti-CD40 antibody, in healthy subjects: a potential novel treatment for autoimmune diseases. J Clin Pharmacol. 2018;58(12):1566\u201377.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"749_CR134","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/art.42557","volume":"75","author":"DR Jayne","year":"2023","unstructured":"Jayne DR, Steffgen J, Romero-Diaz J, Bajema I, Boumpas DT, Noppakun K, et\u00a0al. Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled. Phase II Trial Arthritis Rheumatol. 2023;75(11):1983\u201393.","journal-title":"Phase II Trial Arthritis Rheumatol"},{"key":"749_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.625630","volume":"11","author":"ZZ Wang","year":"2020","unstructured":"Wang ZZ, Song J, Wang H, Li JX, Xiao Q, Yu Z, et\u00a0al. B cell-activating factor promotes B cell survival in ectopic lymphoid tissues in nasal polyps. Front Immunol. 2020;11: 625630.","journal-title":"Front Immunol"},{"key":"749_CR136","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Hern\u00e1ndez J, Ignatenko S, Gordienko A, Agmon-Levin N, Narongroeknawin P, Romanowska-Prochnicka K, et\u00a0al. POS0120 safety and efficacy of subcutaneous (SC) dose IANALUMAB (VAY736; anti-baffr mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE). BMJ Publishing Group Ltd; 2023.","DOI":"10.1136\/annrheumdis-2023-eular.3110"},{"issue":"9","key":"749_CR137","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S, N\u00f6thling DM, Rothe T, Anoshkin K, et\u00a0al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med. 2024;391(9):867\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"749_CR138","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander T, Kr\u00f6nke J, Cheng Q, Keller U, Kr\u00f6nke G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med. 2024;391(9):864\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"749_CR139","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et\u00a0al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"749_CR140","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et\u00a0al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168\u201378.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"749_CR141","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D, et\u00a0al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"749_CR142","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et\u00a0al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"11","key":"749_CR143","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi S, S\u00e1nchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et\u00a0al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"749_CR144","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et\u00a0al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"749_CR145","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et\u00a0al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"749_CR146","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et\u00a0al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"749_CR147","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et\u00a0al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind. Placebo-Controlled Study Arthritis Rheumatol. 2017;69(5):1016\u201327.","journal-title":"Placebo-Controlled Study Arthritis Rheumatol"},{"key":"749_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226051","author":"GS Moysidou","year":"2024","unstructured":"Moysidou GS, Garantziotis P, Sentis G, Nikoleri D, Malissovas N, Nikoloudaki M, et\u00a0al. Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1136\/ard-2024-226051.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"749_CR149","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et\u00a0al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"749_CR150","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"749_CR151","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","volume":"69","author":"C Gordon","year":"2017","unstructured":"Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc analysis of the phase II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 2017;69(1):122\u201330.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"749_CR152","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et\u00a0al. Efficacy and safety of atacicept in patients with systemic Lupus Erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm. Phase IIb Study Arthritis Rheumatol. 2018;70(2):266\u201376.","journal-title":"Phase IIb Study Arthritis Rheumatol"},{"issue":"4","key":"749_CR153","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et\u00a0al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"749_CR154","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, et\u00a0al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74(9):1667\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"749_CR155","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"749_CR156","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1101\/gad.297002.117","volume":"31","author":"K Georgopoulos","year":"2017","unstructured":"Georgopoulos K. The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigma. Genes Dev. 2017;31(5):439\u201350.","journal-title":"Genes Dev"},{"issue":"2","key":"749_CR157","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/S2665-9913(19)30142-0","volume":"2","author":"A Belot","year":"2020","unstructured":"Belot A, Rice GI, Omarjee SO, Rouchon Q, Smith EMD, Moreews M, et\u00a0al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020;2(2):e99\u2013109.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"749_CR158","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/art.39548","volume":"68","author":"CJ Lessard","year":"2016","unstructured":"Lessard CJ, Sajuthi S, Zhao J, Kim K, Ice JA, Li H, et\u00a0al. Identification of a systemic Lupus erythematosus risk locus spanning ATG16L2, FCHSD2, and P2RY2 in Koreans. Arthritis Rheumatol. 2016;68(5):1197\u2013209.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"749_CR159","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1002\/art.39273","volume":"67","author":"F Vu\u010dkovi\u0107","year":"2015","unstructured":"Vu\u010dkovi\u0107 F, Kri\u0161ti\u0107 J, Gudelj I, Teruel M, Keser T, Pezer M, et\u00a0al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015;67(11):2978\u201389.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"749_CR160","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/annrheumdis-2012-202675","volume":"73","author":"HS Lee","year":"2014","unstructured":"Lee HS, Kim T, Bang SY, Na YJ, Kim I, Kim K, et\u00a0al. Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. Ann Rheum Dis. 2014;73(6):1240\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"749_CR161","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ejhg.2012.277","volume":"21","author":"C Wang","year":"2013","unstructured":"Wang C, Ahlford A, J\u00e4rvinen TM, Nordmark G, Eloranta ML, Gunnarsson I, et\u00a0al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur J Hum Genet. 2013;21(9):994\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"21","key":"749_CR162","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.3390\/ijms21218383","volume":"21","author":"TJ Vyse","year":"2020","unstructured":"Vyse TJ, Cunninghame Graham DS. Trans-ancestral fine-mapping and epigenetic annotation as tools to delineate functionally relevant risk alleles at IKZF1 and IKZF3 in systemic lupus erythematosus. Int J Mol Sci. 2020;21(21):8323.","journal-title":"Int J Mol Sci."},{"issue":"10","key":"749_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002341","volume":"7","author":"DS Cunninghame Graham","year":"2011","unstructured":"Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syv\u00e4nen AC, R\u00f6nnblom L, et\u00a0al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011;7(10): e1002341.","journal-title":"PLoS Genet"},{"issue":"11","key":"749_CR164","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41590-019-0490-2","volume":"20","author":"TA Schwickert","year":"2019","unstructured":"Schwickert TA, Tagoh H, Schindler K, Fischer M, Jaritz M, Busslinger M. Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor signaling in B cells. Nat Immunol. 2019;20(11):1517\u201329.","journal-title":"Nat Immunol"},{"issue":"11","key":"749_CR165","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill JT, Werth VP, Furie R, van Vollenhoven R, D\u00f6rner T, Petronijevic M, et\u00a0al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386(11):1034\u201345.","journal-title":"N Engl J Med"},{"issue":"8","key":"749_CR166","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","volume":"81","author":"PE Lipsky","year":"2022","unstructured":"Lipsky PE, Vollenhoven RV, D\u00f6rner T, Werth VP, Merrill JT, Furie R, et\u00a0al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81(8):1136\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"749_CR167","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et\u00a0al. Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic Lupus Erythematosus: results of a phase II, randomized, double-blind. Placebo-Controlled Trial Arthritis Rheumatol. 2021;73(10):1835\u201346.","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"issue":"1","key":"749_CR168","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","volume":"5","author":"DJ Wallace","year":"2023","unstructured":"Wallace DJ, D\u00f6rner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, et\u00a0al. Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic Lupus erythematosus: results of a phase II, randomized, double-blind. Placebo-Controlled Dose-Ranging Trial ACR Open Rheumatol. 2023;5(1):38\u201348.","journal-title":"Placebo-Controlled Dose-Ranging Trial ACR Open Rheumatol"},{"issue":"12","key":"749_CR169","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","volume":"9","author":"Y Hu","year":"2022","unstructured":"Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou L, et\u00a0al. CAR T-cell therapies in China: rapid evolution and a bright future. Lancet Haematol. 2022;9(12):e930\u201341.","journal-title":"Lancet Haematol"},{"issue":"6","key":"749_CR170","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et\u00a0al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"749_CR171","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et\u00a0al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"8","key":"749_CR172","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et\u00a0al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"1","key":"749_CR173","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","volume":"29","author":"S Kretschmann","year":"2023","unstructured":"Kretschmann S, V\u00f6lkl S, Reimann H, Kr\u00f6nke G, Schett G, Achenbach S, et\u00a0al. Successful generation of CD19 chimeric antigen receptor t cells from patients with advanced systemic lupus erythematosus. Transplant Cell Ther. 2023;29(1):27\u201333.","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"749_CR174","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et\u00a0al. Treatment of systemic lupus erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep. 2021;17(6):2120\u20133.","journal-title":"Stem Cell Rev Rep"},{"key":"749_CR175","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1182\/blood-2023-186669","volume":"142","author":"J Feng","year":"2023","unstructured":"Feng J, Yongxian H, Chang AH, Huang H. Cd19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus-safety and preliminary efficacy data from a phase I clinical study. Blood. 2023;142:4835.","journal-title":"Blood"},{"issue":"10","key":"749_CR176","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, et\u00a0al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"749_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100003","volume":"1","author":"SD Reighard","year":"2020","unstructured":"Reighard SD, Cranert SA, Rangel KM, Ali A, Gyurova IE, de la Cruz-Lynch AT, et\u00a0al. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. Cell Rep Med. 2020;1(1): 100003.","journal-title":"Cell Rep Med."},{"issue":"10","key":"749_CR178","volume":"15","author":"N Thangjam","year":"2023","unstructured":"Thangjam N, Dey B, Khonglah Y, Tiewsoh I, Ksoo R. Natural killer cell count in systemic lupus erythematosus patients: a flow cytometry-based study. Cureus. 2023;15(10): e46885.","journal-title":"Cureus"},{"issue":"9","key":"749_CR179","first-page":"1768","volume":"41","author":"H Li","year":"2023","unstructured":"Li H, Geng L, Cao Z, Jin Z, Yan Q, Long X, et\u00a0al. CD56brightCD16- to CD57+CD56dimCD16+ NK cell ratio discriminates disease activity and renal involvement in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2023;41(9):1768\u201376.","journal-title":"Clin Exp Rheumatol"},{"key":"749_CR180","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","volume":"36","author":"S Nagata","year":"2018","unstructured":"Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489\u2013517.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"749_CR181","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.4049\/jimmunol.1000569","volume":"186","author":"Z Huang","year":"2011","unstructured":"Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, et\u00a0al. Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol. 2011;186(6):3421\u201331.","journal-title":"J Immunol"},{"issue":"9","key":"749_CR182","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.4049\/jimmunol.1003349","volume":"186","author":"N Hagberg","year":"2011","unstructured":"Hagberg N, Berggren O, Leonard D, Weber G, Bryceson YT, Alm GV, et\u00a0al. IFN-\u03b1 production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1\u03b2 and LFA-1. J Immunol. 2011;186(9):5085\u201394.","journal-title":"J Immunol"},{"issue":"1","key":"749_CR183","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-021-00726-8","volume":"22","author":"Q Luo","year":"2022","unstructured":"Luo Q, Kong Y, Fu B, Li X, Huang Q, Huang Z, et\u00a0al. Increased TIM-3 (+)PD-1 (+) NK cells are associated with the disease activity and severity of systemic lupus erythematosus. Clin Exp Med. 2022;22(1):47\u201356.","journal-title":"Clin Exp Med"},{"key":"749_CR184","doi-asserted-by":"publisher","first-page":"1380481","DOI":"10.3389\/fimmu.2024.1380481","volume":"15","author":"E Szab\u00f3","year":"2024","unstructured":"Szab\u00f3 E, Farag\u00f3 A, Bodor G, G\u00e9mes N, Pusk\u00e1s LG, Kov\u00e1cs L, et\u00a0al. Identification of immune subsets with distinct lectin binding signatures using multi-parameter flow cytometry: correlations with disease activity in systemic lupus erythematosus. Front Immunol. 2024;15:1380481.","journal-title":"Front Immunol"},{"key":"749_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102856","volume":"132","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang X, Cao X. Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications. J Autoimmun. 2022;132: 102856.","journal-title":"J Autoimmun"},{"issue":"3","key":"749_CR186","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","volume":"51","author":"CA Dutertre","year":"2019","unstructured":"Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et\u00a0al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 2019;51(3):573-89.e8.","journal-title":"Immunity"},{"issue":"5","key":"749_CR187","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/ard-2023-224788","volume":"83","author":"W Chen","year":"2024","unstructured":"Chen W, Jin B, Cheng C, Peng H, Zhang X, Tan W, et\u00a0al. Single-cell profiling reveals kidney CD163 (+) dendritic cell participation in human lupus nephritis. Ann Rheum Dis. 2024;83(5):608\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"749_CR188","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","volume":"38","author":"E Segura","year":"2013","unstructured":"Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et\u00a0al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity. 2013;38(2):336\u201348.","journal-title":"Immunity"},{"key":"749_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621039","volume":"12","author":"SV Parikh","year":"2021","unstructured":"Parikh SV, Malvar A, Shapiro J, Turman JM, Song H, Alberton V, et\u00a0al. A novel inflammatory dendritic cell that is abundant and contiguous to T cells in the kidneys of patients with lupus nephritis. Front Immunol. 2021;12: 621039.","journal-title":"Front Immunol"},{"issue":"12","key":"749_CR190","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrrheum.2016.147","volume":"12","author":"F Coutant","year":"2016","unstructured":"Coutant F, Miossec P. Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles. Nat Rev Rheumatol. 2016;12(12):703\u201315.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"749_CR191","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-010-1709-6","volume":"32","author":"A Henriques","year":"2012","unstructured":"Henriques A, In\u00eas L, Carvalheiro T, Couto M, Andrade A, Pedreiro S, et\u00a0al. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int. 2012;32(4):863\u20139.","journal-title":"Rheumatol Int"},{"issue":"1","key":"749_CR192","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.molimm.2007.04.029","volume":"45","author":"N Fiore","year":"2008","unstructured":"Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, et\u00a0al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol. 2008;45(1):259\u201365.","journal-title":"Mol Immunol"},{"issue":"7","key":"749_CR193","doi-asserted-by":"publisher","first-page":"107173","DOI":"10.1016\/j.isci.2023.107173","volume":"26","author":"KA Monaghan","year":"2023","unstructured":"Monaghan KA, Hoi A, Gamell C, Tai TY, Linggi B, Jordan J, et\u00a0al. CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses. iScience. 2023;26(7):107173.","journal-title":"iScience"},{"issue":"9","key":"749_CR194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells8090963","volume":"8","author":"IT Chyuan","year":"2019","unstructured":"Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells. 2019;8(9):1.","journal-title":"Cells"},{"key":"749_CR195","doi-asserted-by":"crossref","unstructured":"M\u00e4h\u00f6nen K, Hau A, Bondet V, Duffy D, Eklund KK, Panelius J, et\u00a0al. Activation of NLRP3 Inflammasome in the Skin of Patients with Systemic and Cutaneous Lupus Erythematosus. Acta Derm Venereol. 2022; 102: adv00708.","DOI":"10.2340\/actadv.v102.2293"},{"issue":"4","key":"749_CR196","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/jir.2012.0159","volume":"33","author":"NC Reich","year":"2013","unstructured":"Reich NC. A death-promoting role for ISG54\/IFIT2. J Interferon Cytokine Res. 2013;33(4):199\u2013205.","journal-title":"J Interferon Cytokine Res"},{"key":"749_CR197","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.bbi.2023.06.021","volume":"114","author":"E Aw","year":"2023","unstructured":"Aw E, Zhang Y, Yalcin E, Herrmann U, Lin SL, Langston K, et\u00a0al. Spatial enrichment of the type 1 interferon signature in the brain of a neuropsychiatric lupus murine model. Brain Behav Immun. 2023;114:511\u201322.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"749_CR198","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","volume":"21","author":"V Oke","year":"2019","unstructured":"Oke V, Gunnarsson I, Dorschner J, Eketj\u00e4ll S, Zickert A, Niewold TB, et\u00a0al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"749_CR199","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037000","volume":"7","author":"EC Somers","year":"2012","unstructured":"Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, et\u00a0al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE. 2012;7(5): e37000.","journal-title":"PLoS ONE"},{"issue":"2","key":"749_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/lupus-2023-000933","volume":"10","author":"KV Yerram","year":"2023","unstructured":"Yerram KV, Baisya R, Kumar P, Mylavarapu R, Rajasekhar L. Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus. Lupus Sci Med. 2023;10(2):1.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"749_CR201","first-page":"376","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et\u00a0al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, moderate-to-severe systemic lupus erythematosus. arthritis. Rheumatol. 2017;69(2):376\u201386.","journal-title":"Rheumatol"},{"issue":"3","key":"749_CR202","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et\u00a0al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"749_CR203","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et\u00a0al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208\u201319.","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"749_CR204","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","volume":"81","author":"IN Bruce","year":"2022","unstructured":"Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, et\u00a0al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials. Ann Rheum Dis. 2022;81(7):962\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"749_CR205","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","volume":"4","author":"EF Morand","year":"2022","unstructured":"Morand EF, Furie RA, Bruce IN, Vital EM, Dall\u2019Era M, Maho E, et\u00a0al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 2022;4(4):e282\u201392.","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"749_CR206","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et\u00a0al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81(7):951\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"749_CR207","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/ard-2022-222748","volume":"82","author":"EF Morand","year":"2023","unstructured":"Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023;82(5):639\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"749_CR208","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/ard-2023-225445","volume":"83","author":"T Baker","year":"2024","unstructured":"Baker T, Sharifian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, et\u00a0al. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. 2024;83(8):1018\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"749_CR209","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/ard.2010.144485","volume":"70","author":"JT Merrill","year":"2011","unstructured":"Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et\u00a0al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70(11):1905\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"749_CR210","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.37824","volume":"65","author":"M Petri","year":"2013","unstructured":"Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et\u00a0al. Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011\u201321.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"749_CR211","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et\u00a0al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909\u201316.","journal-title":"Ann Rheum Dis"},{"key":"749_CR212","doi-asserted-by":"crossref","unstructured":"Yao Y, Higgs BW, Richman L, White B, Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus. Arthritis Res Ther. 2010;12 Suppl 1 (Suppl 1):S6.","DOI":"10.1186\/ar2887"},{"issue":"1","key":"749_CR213","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","volume":"75","author":"KC Kalunian","year":"2016","unstructured":"Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, et\u00a0al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196\u2013202.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"749_CR214","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, et\u00a0al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387(10):894\u2013904.","journal-title":"N Engl J Med"},{"issue":"6","key":"749_CR215","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/cpt.3216","volume":"115","author":"L Klopp-Schulze","year":"2024","unstructured":"Klopp-Schulze L, Gopalakrishnan S, Yalkinoglu \u00d6, Kuroki Y, Lu H, Goteti K, et\u00a0al. Asia-inclusive global development of enpatoran: results of an ethno-bridging study, intrinsic\/extrinsic factor assessments and disease trajectory modeling to inform design of a phase II multiregional clinical trial. Clin Pharmacol Ther. 2024;115(6):1346\u201357.","journal-title":"Clin Pharmacol Ther"},{"key":"749_CR216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","volume":"207","author":"C Ma","year":"2019","unstructured":"Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1\u20139.","journal-title":"Clin Immunol"},{"issue":"7","key":"749_CR217","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/ard-2023-225433","volume":"83","author":"AG Ferret\u00e9-Bonastre","year":"2024","unstructured":"Ferret\u00e9-Bonastre AG, Mart\u00ednez-Gallo M, Morante-Palacios O, Calvillo CL, Calafell-Segura J, Rodr\u00edguez-Ubreva J, et\u00a0al. Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus. Ann Rheum Dis. 2024;83(7):865\u201378.","journal-title":"Ann Rheum Dis"},{"key":"749_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113916","volume":"146","author":"Z Wang","year":"2025","unstructured":"Wang Z, Yang C, Gao W, Sun W, Sun J, Wang H, et\u00a0al. Systemic lupus erythematosus-specific CD14 (+)IFITM3 (+) monocyte: Implications for disease activity and progression. Int Immunopharmacol. 2025;146: 113916.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"749_CR219","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000480373","volume":"10","author":"RS Doster","year":"2018","unstructured":"Doster RS, Rogers LM, Gaddy JA, Aronoff DM. Macrophage extracellular traps: a scoping review. J Innate Immun. 2018;10(1):3\u201313.","journal-title":"J Innate Immun"},{"key":"749_CR220","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trsl.2024.08.005","volume":"274","author":"A Mu\u00f1oz-Callejas","year":"2024","unstructured":"Mu\u00f1oz-Callejas A, S\u00e1nchez-Abad I, Ramos-Manzano A, San Antonio E, Gonz\u00e1lez-S\u00e1nchez E, Silv\u00e1n J, et\u00a0al. Regulation of monocyte apoptosis and DNA extrusion in monocyte extracellular traps by PSGL-1: relevance in systemic lupus erythematosus. Transl Res. 2024;274:10\u201320.","journal-title":"Transl Res"},{"key":"749_CR221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734008","volume":"12","author":"MM Ahamada","year":"2021","unstructured":"Ahamada MM, Jia Y, Wu X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front Immunol. 2021;12: 734008.","journal-title":"Front Immunol"},{"issue":"12","key":"749_CR222","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208132","volume":"13","author":"AC Labonte","year":"2018","unstructured":"Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, et\u00a0al. Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS ONE. 2018;13(12): e0208132.","journal-title":"PLoS ONE"},{"issue":"1","key":"749_CR223","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10020-024-00866-z","volume":"30","author":"L Zhao","year":"2024","unstructured":"Zhao L, Tang S, Chen F, Ren X, Han X, Zhou X. Regulation of macrophage polarization by targeted metabolic reprogramming for the treatment of lupus nephritis. Mol Med. 2024;30(1):96.","journal-title":"Mol Med"},{"issue":"9","key":"749_CR224","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et\u00a0al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425\u201340.","journal-title":"J Cell Physiol"},{"issue":"2","key":"749_CR225","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00467-020-04734-w","volume":"36","author":"Y Ikezumi","year":"2021","unstructured":"Ikezumi Y, Kondoh T, Matsumoto Y, Kumagai N, Kaneko M, Hasegawa H, et\u00a0al. Steroid treatment promotes an M2 anti-inflammatory macrophage phenotype in childhood lupus nephritis. Pediatr Nephrol. 2021;36(2):349\u201359.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"749_CR226","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41419-024-06708-4","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Yao C, Guo H, Ni X, Zhu R, Wang Y, et\u00a0al. Macrophages communicate with mesangial cells through the CXCL12\/DPP4 axis in lupus nephritis pathogenesis. Cell Death Dis. 2024;15(5):344.","journal-title":"Cell Death Dis"},{"issue":"50","key":"749_CR227","doi-asserted-by":"publisher","first-page":"25222","DOI":"10.1073\/pnas.1908576116","volume":"116","author":"P Mistry","year":"2019","unstructured":"Mistry P, Nakabo S, O\u2019Neil L, Goel RR, Jiang K, Carmona-Rivera C, et\u00a0al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA. 2019;116(50):25222\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"749_CR228","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2020-218338","volume":"80","author":"KR Bashant","year":"2021","unstructured":"Bashant KR, Aponte AM, Randazzo D, Rezvan Sangsari P, Wood AJ, Bibby JA, et\u00a0al. Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus. Ann Rheum Dis. 2021;80(2):209\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"749_CR229","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/art.41395","volume":"72","author":"SH Tay","year":"2020","unstructured":"Tay SH, Celhar T, Fairhurst AM. Low-density neutrophils in systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(10):1587\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"749_CR230","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1136\/annrheumdis-2013-204837","volume":"74","author":"C Carmona-Rivera","year":"2015","unstructured":"Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. 2015;74(7):1417\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"749_CR231","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/art.39153","volume":"67","author":"PC Grayson","year":"2015","unstructured":"Grayson PC, Carmona-Rivera C, Xu L, Lim N, Gao Z, Asare AL, et\u00a0al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015;67(7):1922\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"749_CR232","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12016-020-08804-7","volume":"61","author":"V Mutua","year":"2021","unstructured":"Mutua V, Gershwin LJ. A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics. Clin Rev Allergy Immunol. 2021;61(2):194\u2013211.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"749_CR233","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","volume":"16","author":"KH Lee","year":"2017","unstructured":"Lee KH, Kronbichler A, Park DD, Park Y, Moon H, Kim H, et\u00a0al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2017;16(11):1160\u201373.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"749_CR234","first-page":"1","volume":"8","author":"LJ O'Neil","year":"2019","unstructured":"O\u2019Neil LJ, Kaplan MJ, Carmona-Rivera C. The role of neutrophils and neutrophil extracellular traps in vascular damage in systemic lupus erythematosus. J Clin Med. 2019;8(9):1.","journal-title":"J Clin Med"},{"issue":"2","key":"749_CR235","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/BOR.0000000000000577","volume":"31","author":"H Nishi","year":"2019","unstructured":"Nishi H, Mayadas TN. Neutrophils in lupus nephritis. Curr Opin Rheumatol. 2019;31(2):193\u2013200.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"749_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev. 2024;23(10): 103648.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"749_CR237","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13075-018-1666-0","volume":"20","author":"JA Reynolds","year":"2018","unstructured":"Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, et\u00a0al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018;20(1):173.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"749_CR238","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/ard-2022-223808","volume":"82","author":"MY Choi","year":"2023","unstructured":"Choi MY, Chen I, Clarke AE, Fritzler MJ, Buhler KA, Urowitz M, et\u00a0al. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes. Ann Rheum Dis. 2023;82(7):927\u201336.","journal-title":"Ann Rheum Dis"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-025-00749-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:03:08Z","timestamp":1750071788000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-025-00749-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":238,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s11658-025-00749-z","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not include details, images, or videos relating to an individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}